identifying oxphos dependent tumors across different cancer types daniel gusenleitner adviser:...
TRANSCRIPT
![Page 1: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/1.jpg)
Identifying OxPhos dependent tumors across different cancer types
Daniel GusenleitnerAdviser: Stefano Monti
![Page 2: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/2.jpg)
Monti, Savage, Kutok, et al. Blood, 2005
DLBCL - Oxphos Subtype
![Page 3: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/3.jpg)
OxPhos samples respond to targeted treatment
PPARγ antagonistsCaro et al., Cancer Cell, 2012
![Page 4: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/4.jpg)
Trainings dataset
CCCbiomarker
Developing a biomarker for CCC
BCR HR OxPhos
signatures
Validation on
![Page 5: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/5.jpg)
![Page 6: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/6.jpg)
Goal
Identification of OxPhos samples
across different cancer types
![Page 7: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/7.jpg)
Outline
• Evidence for OxPhos – NonOxPhos stratification in other tumor types
• Most genes of DLBCL OxPhos signature are also present in solid tumors, but we found additional concordant genes
• No evidence of association with genomic instability (mutations and/or SCNAs)
• Strong candidates of OxPhos/Non-OxPhos cell-lines
![Page 8: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/8.jpg)
OxPhos subtype in Melanoma
OxP
hos
Sig
nat
ure
GSEA resultsP
GC
1a
p-value: 0.003711
OxPhos metagene
![Page 9: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/9.jpg)
Datasets
• TCGA– LUAD: lung adenocarcinoma
– LUSC: lung squamous cell carcinoma
– BRCA: breast invasive carcinoma
– HNSC: head and neck squamous carcinoma
• Breast Curtis
• CCLE
![Page 10: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/10.jpg)
Outline
• Evidence for OxPhos – NonOxPhos stratification in other tumor types
• Most genes of DLBCL OxPhos signature are also present in solid tumors, but we found additional concordant genes
• No evidence of association with genomic instability (mutations and/or SCNAs)
• Strong candidates of OxPhos/Non-OxPhos cell-lines
![Page 11: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/11.jpg)
Clustering is not always the best way to define a subtype
OxP
hos
sign
atur
e
DLBCL samples
![Page 12: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/12.jpg)
Differences in background expression levels make classification infeasible
DLBCL Lung Cancer
Ox
Ph
os
met
a g
ene
ex
pre
ssio
n
Additional DLBCL
![Page 13: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/13.jpg)
ASSIGN is able to score the activation of a signature
.. and to identify the genes that are the main drivers of the signature
![Page 14: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/14.jpg)
ASSIGN is able to adjust for differing backgrounds
![Page 15: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/15.jpg)
In BRCA OxPhos is activated in comparison to BCR …
![Page 16: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/16.jpg)
… but a stratification in a heatmap is hard to quantify
![Page 17: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/17.jpg)
Unlike active signatures, the weights for random signatures are exponentially
distributedsc
ale
d g
en
e w
eig
hts
OxPhos signature
active signature
random signatures
![Page 18: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/18.jpg)
p-value: 3.28E-06 p-value: 0.06195
sca
led
ge
ne
we
igh
ts
OxPhos signature BCR signature
Gene weights for inactive signatures cannot be distinguished from weights of random signatures
p-values based on whether the signature follows an exponential distribution
![Page 19: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/19.jpg)
OxPhos appears to be active in all TCGA datasets
Signature Dataset p-value
OxPhos BRCA 0.00162
OxPhos HNSC 1.30E-05
OxPhos LUAD 3.28E-06
OxPhos LUSC 8.84E-06
BCR BRCA 0.08553
BCR HNSC 0.17410
BCR LUAD 0.06195
BCR LUSC 0.00011
![Page 20: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/20.jpg)
We can find the OxPhos signal in all cancer datasets we looked at
![Page 21: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/21.jpg)
Expansion of the OxPhos signature
CCC OxPhos signature:
Derived from DLBCL samples robust (>>FC)high minimum expressionRepresented on U133A
108
General OxPhos signature
BIOCARTA MITOCHONDRIA PATHWAYKEGG OXIDATIVE PHOSPHORYLATION
REACTOME ELECTRON TRANSPORT CHAINREACTOME RESPIRATORY ELECTRON TRANSPORT
OXIDOREDUCTASE ACTIVITY ACTING ON NADH OR NADPHREACTOME TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT
232287
![Page 22: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/22.jpg)
Expanded OxPhos signature in LUAD
DLBCL OxPhos signature
General OxPhos genes
![Page 23: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/23.jpg)
Continuous GSEA to find gene-sets that correlate with ASSIGN score
Cor
rela
tion
with
A
SS
IGN
sco
re
ASSIGN score
DLBCL derived OxPhos signature
Expression Set
![Page 24: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/24.jpg)
Microsoft Office Excel 97-2003 Worksheet
Gene SetAvg. Rank
Curtis discov.
DLBCL 2010
TCGA BRCA
TCGA HNSC
TCGA LUAD
TCGA LUSC
KEGG OXIDATIVE PHOSPHORYLATION 5.8 0.005 NA 0.013 0.007 0.002 0.001
REACTOME METABOLISM OF PROTEINS 8.2 0.001 0.122 0.028 0.003 0 0.001
REACTOME TRANSLATION 9.2 0.002 0.1 0.024 0.003 0.002 0.005
SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE
9.7 0.002 0.079 0.022 0.004 0.004 0.006
MITOCHONDRIAL PROTEIN IMPORT 14 0.005 0.073 0.028 0.003 0.005 0.008
REACTOME METABOLISM OF MRNA 16 0.001 0.3 0.019 0.002 0.001 0.003
REACTOME METABOLISM OF RNA 19.3 0 0.32 0.024 0.003 0.002 0.007
REACTOME CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION
22.7 0.005 0.057 0.024 0.033 0.007 0.01
REACTOME SCFSKP2 MEDIATED DEGRADATION OF P27 P21
23.2 0.006 0.071 0.025 0.028 0.009 0.01
KEGG RIBOSOME 23.3 0.005 0.073 0.023 0.005 0.011 0.008
ASSIGN score GSEA - up
FDR
![Page 25: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/25.jpg)
Microsoft Office Excel 97-2003 Worksheet
ASSIGN score GSEA - down
Gene SetAvg. Rank
Curtis dis
DLBCL 2010
TCGA BRCA
TCGA HNSC
TCGA LUAD
TCGA LUSC
REACTOME NRAGE SIGNALS DEATH THROUGH JNK 30.5 0.03 0.091 0.174 0.022 0.019 0.048
KEGG PHOSPHATIDYLINOSITOL SIGNALING SYSTEM 30.5 0.067 0.086 0.172 0.04 0.025 0.058
KEGG DORSO VENTRAL AXIS FORMATION 38.3 0.031 0.09 0.181 0.033 0.028 0.035
PID RHOA REG PATHWAY 41 0.029 0.088 0.243 0.024 0.031 0.026PID FAK PATHWAY 41 0.045 0.091 0.163 0.046 0.059 0.046ST INTEGRIN SIGNALING PATHWAY 41.2 0.026 0.097 0.168 0.023 0.05 0.038BIOCARTA PAR1 PATHWAY 41.8 0.066 0.1 0.133 0.026 0.035 0.029REACTOME SIGNALING BY RHO GTPASES 42.2 0.035 0.156 0.186 0.026 0.031 0.041
REACTOME BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN EXPRESSION 45.2 0.022 0.096 0.118 0.038 0.027 0.056
PID KITPATHWAY 47.5 0.028 0.195 0.18 0.033 0.072 0.059
FDR
![Page 26: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/26.jpg)
Outline
• Evidence for OxPhos – NonOxPhos stratification in other tumor types
• Most genes of DLBCL OxPhos signature are also present in solid tumors, but we found additional concordant genes
• No evidence of association with genomic instability (mutations and/or SCNAs)
• Strong candidates of OxPhos/Non-OxPhos cell-lines
![Page 27: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/27.jpg)
There is a good concordance between all TCGA sets
Signatures’ overlap
![Page 28: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/28.jpg)
Good concordance between OxPhos signature and TCGA sets
Lymphoma- derived
signature
![Page 29: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/29.jpg)
There are additional genes in the solid tumors
35 nonDLBCL genes
2010
![Page 30: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/30.jpg)
Outline
• Evidence for OxPhos – NonOxPhos stratification in other tumor types
• Most genes of DLBCL OxPhos signature are also present in solid tumors, but we found additional concordant genes
• No evidence of association with genomic instability (mutations and/or SCNAs)
• Strong candidates of OxPhos/Non-OxPhos cell-lines
![Page 31: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/31.jpg)
Looking for link to genomic instability - GISTIC
DEL 1
DEL 2
DEL N
AMP 1
AMP 2
AMP N
…
…
…
…
TCGA samples
CNV profile
ASSIGN score
pVal 1
pVal 2
pVal N
pVal 1
pVal 2
pVal N
…
…
KS - test
Sig
nific
ant
CN
Vs
(>0.
99 c
onfid
ence
)
![Page 32: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/32.jpg)
The only significantly enriched deletion peak is enriched in the intermediate cases
DEL 3
![Page 33: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/33.jpg)
Looking for link to genomic instability - MutSigCV
Gene 1
Gene 2
Gene 3
Gene X
Gene Y
Gene Z
… …
TCGA samples
Mut profile
ASSIGN score
pVal 1
pVal 2
pVal 3
pVal X
pVal Y
pVal Z
…
KS - test
Sig
nific
ant
Mut
atio
ns
(<0.
25 F
DR
)
![Page 34: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/34.jpg)
There is only one enriched mutation across all TCGA datasets
TBL1XR1
![Page 35: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/35.jpg)
Outline
• Evidence for OxPhos – NonOxPhos stratification in other tumor types
• Most genes of DLBCL OxPhos signature are also present in solid tumors, but we found additional concordant genes
• No evidence of association with genomic instability (mutations and/or SCNAs)
• Strong candidates of OxPhos/Non-OxPhos cell-lines
![Page 36: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/36.jpg)
Testing “OxPhosness” in cell-lines
CCLE - pVal Predictions
Lung 5.53E-06
Lung adeno 0.0073
Lung small cell 0.0154
Lung squamous 0.0553
Breast 5.08E-05
HNCC 5.67E-05
Melanoma 0.001
breast
HNCC
Lung
Lung small cell
Lung squamous
Breast
hncc
Lung
Lung adeno
Lung small cell
Lung squamous
Lung adeno
melanoma melanoma
![Page 37: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/37.jpg)
Lun
g A
den
oca
rcinom
a
Cell-lin
es
Cellline CCLE_score CCLE_probNCI-H1355 0.175 1
HCC-2279 0.193 1
NCI-H1651 0.209 1
NCI-H1573 0.216 1
NCI-H2023 0.232 1
SK-LU-1 0.236 1
MOR/CPR 0.262 1
NCI-H1703 0.269 1
NCI-H2087 0.271 1
Calu-3 0 0
HCC-44 0 0
LXF-289 0 0
NCI-H1373 0 0
NCI-H2009 0 0
NCI-H2085 0 0
NCI-H322 0 0
NCI-H3255 0 0
NCI-H854 0 0
RERF-LC-Ad1 0 0
RERF-LC-Ad2 0 0
![Page 38: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/38.jpg)
Bre
ast C
an
cer
Cell-lin
es
Cellline CCLE_score CCLE_probEVSA-T 0.985 1
SK-BR-3 0.885 1
YMB-1 0.879 1
AU565 0.878 1
ZR-75-1 0.837 1
HCC2218 0.83 1
EFM-192A 0.784 1
MDA-MB-453 0.777 1
MCF7 0.773 1
CAL-148 0.758 1
HDQ-P1 0.027 0.198901
HCC1143 0.001 0.013993
Hs 742.T 0.001 0.009495
HCC1806 0 0.003998
Hs 606.T 0 0.001999
Hs-578-T 0 0.0005
Hs 274.T 0 0.0005
Hs 739.T 0 0.0005
Hs 281.T 0 0
Hs 343.T 0 0
![Page 39: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/39.jpg)
HN
CC
Cell-lin
es
Cellline CCLE_score CCLE_probFADU 0.937 1
SNU-1214 0.911 1
SNU-46 0.831 1
HSC-3 0.787 1
PE/CA-PJ34 (clone C12) 0.728 1
SNU-1041 0.715 1
BICR 18 0.708 1
YD-15 0.689 1
CAL-27 0.679 1
BICR 16 0.673 1
SNU-1066 0.165 0.746127
BICR 22 0 0.002499
BHY 0 0
BICR 56 0 0
SCC-9 0 0
SNU-1076 0 0
![Page 40: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/40.jpg)
Future Work
• Functional validation of the top and bottom cell-lines
• Association with TCGA methylation data
![Page 41: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/41.jpg)
Conclusion
• Evidence for OxPhos – NonOxPhos stratification in other tumor types
• Most genes of DLBCL OxPhos signature are also present in solid tumors, but we found additional concordant genes
• No evidence of association with genomic instability (mutations and/or SCNAs)
• Strong candidates of OxPhos/Non-OxPhos cell-lines
![Page 42: Identifying OxPhos dependent tumors across different cancer types Daniel Gusenleitner Adviser: Stefano Monti](https://reader036.vdocuments.us/reader036/viewer/2022070408/56649e525503460f94b47cc8/html5/thumbnails/42.jpg)
Acknowledgements
Stefano Monti
Ying Shen
Liye Zhang
Francesca Mulas
Yuxiang Tan
Evan Johnson
Marc Lenburg
Luis Carvalho
Björn ChapuyNika DanialMargaret Shipp